methodology and to molecular mechanisms of these hallmarks of cancer malignancy. His current publications emphasize the ecosystem concept implicating a continuous interaction between cancer cells and tumor-associated host cells, and the effects of treatment on the "ecosystems of invasion and metastasis".
Professor Mareel, we know you as an internationally recognized pioneer of invasion and metastasis research. When and how did your interest in cancer research start?
In my third year as a medical student, I met with Prof. Lucien Vakaet (1926 Vakaet ( -1996 , who was supervising the practical course of dissection at the Department of Anatomy, headed by Prof. Julien Fautrez (1914 -1996 (Fig. 1) . He "infected me with the virus of scientific research" as quoted in his interview by P. Van Gansen (1992) . Vakaet was an internationally renowned avian embryologist. He not only permitted me to participate at his experiments on early chick blastoderms (Vakaet and Mareel, 1964) but also provided me, as a student-assistent, with a salary that together with the generous support of my parents let me do research and study medicine during 4 years without financial concern. L.Vakaet had brought the organotypic culture technique to Ghent from his stay at the Laboratory of Prof. E. Wolff in Strasbourg (1955) . When one of my fellow students decided to leave research for full time clinical work, L. Vakaet passed to me the project on development of the embryonic chick tibia in organ culture (Mareel, 1967) . The results won me a journey to the Chester Beatty Research Institute, London, where I worked with G. and D. Easty, pioneers in cancer invasion research (Easty and Easty, 1963) , and with J. Ambrose, a physicochemist with great interest in cancer cell biology. Under L. Vakaet, I also did the research for my "Aggregaat Hoger Onderwijs", a PhD equivalent, about transplantation of cancer cells into young chick blastoderms (1972), a quite obvious combination of his interest in early bird embryology and my unexplained wish to do cancer research. (Fig. 2) This clarifies indeed your genuine interest in experimental cancer studies, but still I wonder how your research and your clinical activities are related to each other.
After my medical degree (1964) , I wanted to do cancer research, yet keeping close contact with clinical oncology. A good advice came, again, from L. Vakaet. "Look for a place at the University Hospital where the Head of Department allows such combination and provides space and money to start your own laboratory" he spelled out. That is exactly what I found at the department of Radiotherapy and Nuclear Medicine (Director, Prof. dr. P. M. Van Vaerenbergh, 1904 -1977 . So, my choice for Radiotherapy as a profession was not primarily inspired by a genuine interest in this discipline per se. After one year, L. de Ridder joined the effort and together we have built the Laboratory of Experimental Cancer Research, first at the Bijloke site and later at the Campus Heymans, until he left to become a Professor of Histology at our University (Fig. 3) .
During my entire career I have combined experimental cancer research and clinical radiotherapy-oncology with great satisfac- Vakaet (1960 Vakaet ( -1964 (1964) (1965) (1966) (1967) (1968) (1969) (1964) (1965) (1966) (1967) (1968) (1969) 
left). Photographs were taken in 1972 (D) and August 2011 (A, B and C).
that it was, and still is, not too difficult to find good places where you can combine both.
There are many examples of medical doctors who have combined research and clinical practice. To give just two examples. Prof. J.-M. Foidart from the Université de Liège, is closely related to mammary cancer. He and his students are practicing gynecologists who have contributed greatly to our understanding of basic mechanisms of cancer metastasis and they and their school continue to do so. My second example, Prof. G. Storme, is one of my first students. He has built at the VUB (Flemish University Brussels) one of the most advanced radiotherapy departments, performing clinical work at the highest academic level. It gives me great pleasure that his department harbours a research laboratory that yielded valuable contributions to the molecular understanding of hypoxia-related radioresistance.
At the age of my pension (2003), I was lucky enough to get the opportunity to continue my double activity but now without the burden of all the administrative work that is the privilege of a Head of Department. As a result, my second paper in clinical radiotherapy appeared 3 years ago (Veldeman et al., 2008) , 40 years after my first one (Mareel and Van Vaerenbergh, 1968) . My latest research paper is about the effects of ionizing radiation on invasion and metastasis in a murine model of metastatic mammary cancer (Vala et al., 2010) ; it gave me as much satisfaction as my first research paper, almost 50 years ago.
You mentioned your special interest in the effects of ionizing radiation on invasion and metastasis. What were the other major topics in your cancer research?
After my PhD thesis on chick blastoderm transplantations (Mareel et al., 1975) , I turned my attention to models of invasion in vitro and in vivo that were closer to reality. Much attention was paid to invasion in organ culture, a technique that I learned as a student. E. Wolff used embryonic tissue, mostly mesonephros, as a source of growth factors for human cancer cells. For subculturing and expanding the cancer cell population, he separated the mesonephros from the cancer cells by a piece of vitelline membrane. Removing the membrane brought cancer cells into direct contact with the normal tissue and so provided us with a model for invasion (de Ridder et al., 1977) .
The aim of my research was, and still is, understanding the mechanisms of cancer invasion and metastasis. Within this topic, the direction of my research has been very much influenced by contact with other researchers inside or outside the laboratory (Fig. 4 ).
An encounter with Marc De Brabander (1943 -2011 , working at Janssen Pharmaceutica in Beerse, Belgium, brought microtubule inhibitors into the laboratory as powerful inhibitors of invasion (Mareel and De Brabander, 1978) . Translation into therapy was, however, hampered by the fact that antiinvasive doses of these drugs were also cytotoxic.
Your (Marc Bracke) arrival introduced extracellular matrix with emphasis on cartilage because it appeared to be resistant to invasion (Bracke et al., 1984) and basement membrane matrix because it distinguished between invasive and noninvasive cells. Later, you also introduced a specific interest for hormonal influences on tion. I spent the last decade of my career (1991 -2003) (Bracke et al., 1994) , and you still use our original chick heart invasion model (Mareel et al., 1979) for the screening of drugs in vitro (Katritzky et al., 2006) . Walter Fiers, Professor of Biochemistry at our University, persuaded me to look at the role of oncogenes in invasion and introduced me to his PhD student Frans van Roy. This resulted in a long and very fruitful collaboration first on oncogenes (Van Roy et al., 1986) and thereafter on the cell-cell adhesion molecule E-cadherin , that we characterized as an invasion-suppressor gene product, regulated at various levels Vermeulen et al., 1995; Comijn et al., 2001) . I brought E-cadherin to Ghent after a meeting with Walter Birchmeier in the late eighties (Behrens et al., 1989) . There are two other topics that I have tackled with great enthusiasm: one, the invasive and metastatic characteristics of micro-organisms as compared to metastatic cancer cells; two, the crucial role of tumor-associated host cells in cancer invasion. The first topic was inspired by a meeting in the vicinity of Lugano, co-organized by Philippe Sansonetti from the Pasteur Institute in Paris and materialized by two brilliant students who worked on Entamoeba histolytica (Leroy et al., 2000) and on Listeria monocytogenes (Oliveira et al., 2003) . The other topic was on my mind since Patrick De Baetselier reported results from his work at the Weizmann Institute in Rehovot, Israel, showing that normal B-lymphocytes could convey metastatic capability upon plasmocytoma cells (De Baetselier et al., 1981) . Experiments started when François Martin, an immunologist from Dijon, France, asked us to characterize some of his rat colon cancer cell lines in our invasion models. It appeared that none of these cancer cells were invasive unless myofibroblasts were added to the system (Dimanche-Boitrel et al., 1994) . Since, tumor-associated host cells are a major topic in our laboratory (De Wever et al., 2004; De Wever et al., 2008) . To summarize, I think that we have contributed some valuable pieces to the puzzle, though the question when, why and how cancer does metastasize remains unanswered. My actual way of thinking about this problem follows the ecosystem concept (Mareel and Constantino, 2011) .
Looking at the impressive publication list from your lab, I was struck by the high number of papers on mammary cancer. Yet, you did not mention mammary cancer as one of your favorite topics. Why is that?
Since there is, as yet, no good evidence to accept that the mechanisms of invasion and metastasis are fundamentally different in breast cancer as compared to most other epithelial cancers, I have not focused my research on any particular cancer type. Nevertheless, mammary cancer has crossed my path many times indeed. In the laboratory these encounters were due to the choice of appropriate material, tumors or cell lines, for a given experiment and to the interest of some collaborators in the hormonal aspects of breast cancer. In the clinic, they were the consequence of the high frequency of breast cancer and the indispensable place of radiotherapy in its treatment. Searching PubMed for "Mareel M AND breast cancer" yields 37 papers, the first -one of my rare clinical papers -in 1968 (Mareel and Van Vaerenbergh, 1968 ) and the latest -covering my new interest in ionizing radiation and invasion -in 2010 (Vala et al., 2010) . The breast cancer link is mainly through the choice of cell lines like MCF-7. An additional search for "Mareel M AND mammary gland" reveals 6 more papers in which the normal murine mammary gland cell family, coined NMuMG, plays a major role. One of these papers is my most cited one , cited 1,107 times) (Fig. 5) .
Let me ask you a question that applies to mammary cancer more specifically: have you observed advances in its treatment since the start of your medical career?
Beyond the shadow of a doubt, yes, treatment of breast cancer has improved substantially. Side effects of all forms of treatment have decreased and cure rate has increased. Today, locoregional control under very acceptable conditions is achieved in most patients, distant metastasis being the cause of death in those patients that die from their disease, a serious motivation for my research.
My contact with breast cancer started in the early sixties, when I was a medical student. Then, all patients underwent extensive surgery through the procedure launched by William Steward Halsted around 1880. It consisted in resection of the whole breast, including pectoralis muscles and as much of the axillary lymph nodes as feasible. The fact that this mutilating procedure persisted for almost one century is easily understood as it heralded a cure rate of 50 % for a disease that, before Halsted, killed most of the patients. In the seventies much more limited surgery with removal of the tumor only and diagnostic exploration of the axilla started to replace the Halsted procedure, which was abandoned completely after publication of high level evidence from clinical trials comparing mastectomy with tumorectomy plus radiotherapy. The biological basis for this change was launched by Georges Crile (1950s) and Bernard Fisher (1970s) , stating that breast cancer is a systemic disease and that the seeds of metastasis have escaped already at the moment of surgery rather than a locoregional disease that can be removed before it spreads. This statement is confirmed by all experimental and clinical evidence published since. Added to locoregional treatment is adjuvant chemotherapy and hormonotherapy. The latter was initiated by George Thomas Beatson performing oophorectomy at the end of the nineteenth century and later extended with adrenalectomy and hypophysectomy. These debilitating procedures were replaced in the eighties by the estrogen receptor antagonist tamoxifen, an oral drug with few side effects and quite good results in patients with tumors expressing estrogen receptors. In the same period, bisphosphonates were introduced in the clinic: they are inhibitors of osteoclasts and useful for the palliative treatment of bone metastasis. Determination of estrogen receptors is an early example of selection of patients for treatment on the basis of molecular tumor characteristics. More recently, routine determination of hormone receptors was added with measurement of the growth factor tyrosine kinase receptor c-ErbB2 (HER-2/neu) for selection of patients that possibly respond I would attempt to individualize treatment and evaluate responses during the treatment on the basis of molecular characterization of the tumor before and during treatment.
I am, nevertheless, firmly convinced that we cannot afford reducing support for fundamental research. For, it might well be that the fundamental discovery that will lead to full understanding and successful treatment of cancer remains to be made (Fig. 7) . to the monoclonal antibody Herceptin (trastuzumab). The last decade has seen an explosion of genetic and genomic findings that await translation into preventive, diagnostic and therapeutic practice. A serious obstacle for this most interesting translational project is financial support for independent academic research. The National Cancer Plan, installed in 2007, constitutes an invaluable initiative to tackle this problem (Fig. 6) . Today, translational research is rightly much emphasized; there are myriads of laboratory results that await clinical application. If I would start working on breast cancer, I would go for distinction between metastatic and nonmetastatic tumors with focus on inflammation, circulating tumor cells and bone marrow responses, with the aim to restrict systemic therapy to subgroups of patients. Within the latter cohort,
Taking into consideration your

